Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors (NCT04165772)
A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
Who can join: Review the eligibility criteria below.
Location: Hartford Healthcare (Data Collection) — Hartford, Connecticut
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- Hartford Healthcare (Data Collection) — Hartford, Connecticut
- Baptist Alliance MCI (Data Collection Only) — Miami, Florida
- Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth - Limited Protocol Activities — Middletown, New Jersey
- Memorial Sloan Kettering Bergen - Limited Protocol Activities — Montvale, New Jersey
- Memorial Sloan Kettering Commack - Limited Protocol Activities — Commack, New York
- Memorial Sloan Kettering Westchester - Limited Protocol Activities — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau - Limited Protocol Activities — Uniondale, New York
- Lehigh Valley Health Network (Data Collection Only) — Allentown, Pennsylvania
📞 Contact the Study Coordinator
Phone: (646) 888-4189
Email: cerceka@mskcc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Rectal Adenocarcinoma
- Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma — Tampa, Florida
- ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer — Portland, Oregon
- ctDNA-Informed Management of Early-Stage Rectal Cancer — Sacramento, California
- Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer — Houston, Texas
- Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer — Portland, Oregon
Explore by condition: All Rectal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.